These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 24983206)

  • 21. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA).
    Itani KM; Weigelt J; Li JZ; Duttagupta S
    Int J Antimicrob Agents; 2005 Dec; 26(6):442-8. PubMed ID: 16289514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany.
    Schürmann D; Sorensen SV; De Cock E; Duttagupta S; Resch A
    Eur J Health Econ; 2009 Feb; 10(1):65-79. PubMed ID: 18437437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical efficacy of oral linezolid compared with intravenous vancomycin for the treatment of methicillin-resistant Staphylococcus aureus-complicated skin and soft tissue infections: a retrospective, propensity score-matched, case-control analysis.
    Itani KM; Biswas P; Reisman A; Bhattacharyya H; Baruch AM
    Clin Ther; 2012 Aug; 34(8):1667-73.e1. PubMed ID: 22770644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidemiology and outcomes of complicated skin and soft tissue infections in hospitalized patients.
    Zervos MJ; Freeman K; Vo L; Haque N; Pokharna H; Raut M; Kim M
    J Clin Microbiol; 2012 Feb; 50(2):238-45. PubMed ID: 22116149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How complicated skin and soft tissue infections are treated in Italy: economic evaluation of inpatient intravenous antibiotic treatment in seven hospitals.
    Tarricone R; Aguzzi G; Capone A; Caravaggi CM; Esposito S; Franzetti F; Muzzi A; Ricci L; Bassetti M
    J Med Econ; 2008; 11(2):265-79. PubMed ID: 19450085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and tolerability of tigecycline for the treatment of complicated skin and soft-tissue and intra-abdominal infections: an analysis based on five European observational studies.
    Guirao X; Sánchez García M; Bassetti M; Bodmann KF; Dupont H; Montravers P; Heizmann WR; Capparella MR; Simoneau D; Eckmann C
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii37-44. PubMed ID: 23772045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tigecycline in the Treatment of Patients with Necrotizing Skin and Soft Tissue Infections Due to Multiresistant Bacteria.
    Eckmann C; Heizmann W; Bodmann KF; von Eiff C; Petrik C; Loeschmann PA
    Surg Infect (Larchmt); 2015 Oct; 16(5):618-25. PubMed ID: 26115414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus.
    Sharpe JN; Shively EH; Polk HC
    Am J Surg; 2005 Apr; 189(4):425-8. PubMed ID: 15820454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Future pharmacoeconomic criteria for the treatment of infections.
    Milkovich G
    Int J Antimicrob Agents; 2009 Jul; 34 Suppl 1():S12-4. PubMed ID: 19560668
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidemiology and outcome of invasive fungal infections and methicillin-resistant Staphylococcus aureus (MRSA) pneumonia and complicated skin and soft tissue infections (cSSTI) in Lebanon and Saudi Arabia.
    Moghnieh R; Alothman AF; Althaqafi AO; Matar MJ; Alenazi TH; Farahat F; Corman SL; Solem CT; Raghubir N; Macahilig C; Stephens JM
    J Infect Public Health; 2017; 10(6):849-854. PubMed ID: 28487208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minimally invasive drainage of subcutaneous abscesses reduces hospital cost and length of stay.
    Wright TN; Gilligan L; Zhurbich O; Davenport DL; Draus JM
    South Med J; 2013 Dec; 106(12):689-92. PubMed ID: 24305529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inappropriate initial antibiotic treatment for complicated skin and soft tissue infections in hospitalized patients: incidence and associated factors.
    Lipsky BA; Napolitano LM; Moran GJ; Vo L; Nicholson S; Kim M
    Diagn Microbiol Infect Dis; 2014 Jun; 79(2):273-9. PubMed ID: 24661685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges.
    Cosgrove SE; Qi Y; Kaye KS; Harbarth S; Karchmer AW; Carmeli Y
    Infect Control Hosp Epidemiol; 2005 Feb; 26(2):166-74. PubMed ID: 15756888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Should the methicillin-resistant Staphylococcus aureus carriage status be used as a guide to treatment for skin and soft tissue infections?
    Reber A; Moldovan A; Dunkel N; Emonet S; Rohner P; Tahintzi P; Hoffmeyer P; Harbarth S; Uçkay I
    J Infect; 2012 May; 64(5):513-9. PubMed ID: 22327191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of linezolid in methicillin-resistant Staphylococcus aureus skin and skin structure infections.
    Bounthavong M; Hsu DI
    Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):683-98. PubMed ID: 23252352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Empiric antimicrobial therapy for pediatric skin and soft-tissue infections in the era of methicillin-resistant Staphylococcus aureus.
    Elliott DJ; Zaoutis TE; Troxel AB; Loh A; Keren R
    Pediatrics; 2009 Jun; 123(6):e959-66. PubMed ID: 19470525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus.
    Itani KM; Dryden MS; Bhattacharyya H; Kunkel MJ; Baruch AM; Weigelt JA
    Am J Surg; 2010 Jun; 199(6):804-16. PubMed ID: 20227056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early versus later response to treatment in patients with community-acquired pneumonia: analysis of the REACH study.
    Blasi F; Ostermann H; Racketa J; Medina J; McBride K; Garau J;
    Respir Res; 2014 Jan; 15(1):6. PubMed ID: 24450444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Skin, soft tissue, bone, and joint infections in hospitalized patients: epidemiology and microbiological, clinical, and economic outcomes.
    Lipsky BA; Weigelt JA; Gupta V; Killian A; Peng MM
    Infect Control Hosp Epidemiol; 2007 Nov; 28(11):1290-8. PubMed ID: 17926281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections.
    Edelsberg J; Berger A; Weber DJ; Mallick R; Kuznik A; Oster G
    Infect Control Hosp Epidemiol; 2008 Feb; 29(2):160-9. PubMed ID: 18179372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.